NCT02218307

Brief Summary

Double blind placebo controlled trial to evaluate whether the routine use of nasal irrigation with mupirocin is more effective than saline irrigations alone in reducing symptoms of chronic rhinosinusitis in the early postoperative period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2011

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

July 10, 2014

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 18, 2014

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
1.8 years until next milestone

Results Posted

Study results publicly available

March 9, 2017

Completed
Last Updated

June 26, 2017

Status Verified

May 1, 2017

Enrollment Period

3.6 years

First QC Date

July 10, 2014

Results QC Date

September 28, 2016

Last Update Submit

May 30, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Quality of Life in Chronic Rhinosinusitis Patients

    Measuring the quality of life in chronic rhinosinusitis through completion of a questionnaire named SNOT 20 ( 20 questions for Sino-Nasal Outcome Test) Snot20: Scale 1 to 5 for 20 symptoms numbered below where 5 is the worst symptom. Total SNOT is scale from 0-100 where 100 is the worst. The following are the elements: 1\. need to blow 2. sneezing 3. runny nose 4. cough 5. postnasal drip 6. Thick nasal discharge 7. Ear fullness 8. Dizziness 9. Ear pain 10. facial pain/pressure 11. difficulty falling asleep 12. wake up at night 13. lack of a good night's sleep 14. wake up tired 15. Fatigue 16. Reduced productivity 17. Reduced concentration 18. frustrated/ restless/irritable 19. sad 20. Embarrassed

    3 months

Secondary Outcomes (1)

  • Quality of Life in Chronic Rhinosinusitis Patients

    3 months

Study Arms (2)

Mupirocin

ACTIVE COMPARATOR

topical antibiotic

Drug: Mupirocin

Placebo

PLACEBO COMPARATOR

Placebo control for mupirocin

Drug: Placebo

Interventions

Mupirocin
Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Chronic Rhinosinusitis
  • Undergoing endoscopic sinus surgery

You may not qualify if:

  • Age under 18
  • Documented adverse reaction to mupirocin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Miami Miller School of Medicine, ENT Dept

Miami, Florida, 33136, United States

Location

MeSH Terms

Interventions

Mupirocin

Intervention Hierarchy (Ancestors)

Epoxy CompoundsEthers, CyclicEthersOrganic ChemicalsPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsFatty AcidsLipids

Results Point of Contact

Title
Dr. Roy Casiano
Organization
University of Miami

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 10, 2014

First Posted

August 18, 2014

Study Start

November 1, 2011

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

June 26, 2017

Results First Posted

March 9, 2017

Record last verified: 2017-05

Locations